Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine plus lintuzumab vs low-dose cytarabine plus placebo in older adults with previously untreated AML
2007-004761-17Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Low-dose cytarabine + lintuzumab with Low-dose cytarabine + placebo (2 arms). Primary endpoint: Overall survival. Started Mar 2008; status: terminated.
02
Drugs
lintuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-004761-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004761-17.